NASDAQ:AGIO

Agios Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy AGIO

*Your capital is at risk

$27.68

+1.17 (+4.41%)

At Close: Jun 03, 2026

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

11:05am, Thursday, 08'th Feb 2024

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

07:00am, Friday, 02'nd Feb 2024

CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

07:00am, Monday, 08'th Jan 2024

– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia –

Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case

06:40am, Friday, 05'th Jan 2024

Agios Pharmaceuticals completed its IPO in 2013 and sold its oncology portfolio for $1.8bn in 2021. Its stock price is down 50% across a 5-year period. The company's focus is now on mitapivat, which h

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

12:47pm, Thursday, 04'th Jan 2024

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?

09:02am, Thursday, 04'th Jan 2024

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder

06:49am, Wednesday, 03'rd Jan 2024

Agios Pharmaceuticals Inc.'s stock AGIO, +2.51% soared 19.6% early Wednesday, after the biotech announced positive results from a Phase 3 trial of a treatment for a rare blood disorder. The trial dubb

Agios' blood disorder drug meets goals of late-stage study

06:42am, Wednesday, 03'rd Jan 2024

Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder.

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

07:00am, Tuesday, 02'nd Jan 2024

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha

Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment

12:02pm, Tuesday, 21'st Nov 2023

Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

12:47pm, Friday, 03'rd Nov 2023

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

09:05am, Thursday, 02'nd Nov 2023

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advanc

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by